or Try an Advanced Search...

    Technical Analysis for IPHA - Innate Pharma S.A.

    Grade Last Price % Change Price Change
    D 2.51 -4.68% -0.12
    IPHA closed up 2.33 percent on Wednesday, May 8, 2024, on 5 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: May 14
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Flat Up
    Historical IPHA trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish -4.68%
    MACD Bullish Centerline Cross Bullish -4.68%
    Narrow Range Bar Range Contraction -4.68%
    Above Upper BB Strength -4.68%
    Overbought Stochastic Strength -4.68%
    Upper Bollinger Band Touch Strength -4.68%
    Crossed Above 50 DMA Bullish -2.45%
    Stochastic Reached Overbought Strength -2.45%
    Overbought Stochastic Strength -2.45%
    Fell Below 50 DMA Bearish 0.68%
    Older End-of-Day Signals for IPHA ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 32 minutes ago
    60 Minute Opening Range Breakdown about 1 hour ago
    Fell Below 50 DMA about 1 hour ago
    60 Minute Opening Range Breakout about 1 hour ago
    Gapped Down (Full) about 4 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    IPHA Chart by TradingView
    Basic chart:

    Profile

    Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Immunotherapy Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Antibody Inflammatory Diseases Immunity

    Is IPHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 7 Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
    Apr 15 Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
    Apr 15 Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
    Apr 10 All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
    Apr 10 Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
    Apr 9 Innate Pharma Announces Its Participation in Upcoming Investor Conference
    Apr 5 Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
    Mar 22 Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
    Mar 21 Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript
    Mar 21 Innate Pharma GAAP EPS of -€0.09, revenue of €61.64M
    See more IPHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.57
    52 Week Low 1.81
    Average Volume 10,095
    200-Day Moving Average 2.62
    50-Day Moving Average 2.51
    20-Day Moving Average 2.46
    10-Day Moving Average 2.48
    Average True Range 0.16
    RSI (14) 55.95
    ADX 18.58
    +DI 25.97
    -DI 13.45
    Chandelier Exit (Long, 3 ATRs) 2.16
    Chandelier Exit (Short, 3 ATRs) 2.72
    Upper Bollinger Bands 2.62
    Lower Bollinger Band 2.30
    Percent B (%b) 1.02
    BandWidth 12.89
    MACD Line 0.01
    MACD Signal Line -0.01
    MACD Histogram 0.0229
    Fundamentals Value
    Market Cap 212.61 Million
    Num Shares 80.8 Million
    EPS -0.85
    Price-to-Earnings (P/E) Ratio -3.09
    Price-to-Sales 3.87
    Price-to-Book 3.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.74
    Resistance 3 (R3) 2.72 2.68 2.72
    Resistance 2 (R2) 2.68 2.65 2.68 2.71
    Resistance 1 (R1) 2.65 2.63 2.67 2.67 2.71
    Pivot Point 2.61 2.61 2.61 2.61 2.61
    Support 1 (S1) 2.58 2.58 2.60 2.60 2.55
    Support 2 (S2) 2.54 2.56 2.54 2.55
    Support 3 (S3) 2.51 2.54 2.54
    Support 4 (S4) 2.53